|  | Cancer | Cancer Treatment

Combination Therapy for Advanced Malignant Melanoma: Efficacy & Prognosis

Combination Therapy in Advanced Melanoma

Success depends on drug combination, disease stage, and patient response. While combinations improve outcomes, prognosis for advanced melanoma remains challenging.

Key Combination Regimens

1. Immune Checkpoint Inhibitors (ICIs) + Targeted Therapy

Example: Pembrolizumab/nivolumab + dabrafenib + trametinib (for BRAF-mutant melanoma).

  • Phase 3 trial: Dabrafenib + trametinib + nivolumab (DTN) vs. dabrafenib + trametinib.
  • Median PFS: 16.6 vs. 11.1 months.
  • Median OS: 25.9 vs. 17.9 months.

2. ICI Combinations

Pembrolizumab + ipilimumab:

  • Median PFS: 6.9 months.
  • Median OS: 22.8 months.

3. ICI + Chemotherapy

Pembrolizumab + carboplatin/paclitaxel vs. chemo alone:

  • Median PFS: 6.9 vs. 4.6 months.
  • Median OS: 16.3 vs. 12.1 months.

Challenges & Future Directions

  • Acquired resistance over time.
  • Need for effective second-line therapies.
  • Ongoing trials exploring novel immunotherapy/targeted therapy combinations.

Cancer Treatment - Related Articles